Current gene therapies to treat sickle cell disease are complex, time-consuming, and are sometimes linked to serious side effects like infertility or blood cancer. To address these challenges, Johns Hopkins researchers have developed special nanoparticles that can send gene treatment directly to various types of cells in bone marrow to correct the disease-causing mutations.
